Abstract: Drug resistance remains a formidable challenge in cancer therapy, often driven by the overexpression of anti-apoptotic Bcl-2 family proteins. ABT-737 is a pioneering small-molecule BH3-mimetic designed to specifically bind and inhibit anti-apoptotic proteins such as Bcl-2, Bcl-xL, and Bcl-w. By mimicking the action of pro-apoptotic BH3-only proteins, ABT-737 restores the intrinsic apoptotic pathway in malignant cells. This comprehensive review explores the role of ABT-737 in reversing drug resistance across various malignancies, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), pediatric hepatoblastoma (HB), and hematological cancers. We detail its pharmacological activity, molecular mechanisms, and structure-activity relationships. Furthermore, we discuss the current clinical limitations of ABT-737, such as poor oral bioavailability, dose-limiting thrombocytopenia, and resistance mediated by MCL-1 overexpression, while highlighting future perspectives including synergistic combination therapies and the development of next-generation Bcl-2 inhibitors.
1. Introduction
The development of drug resistance and the occurrence of metastases are major hurdles in the successful treatment of various cancers, often leading to treatment failure and poor patient prognosis [1]. A primary mechanism by which tumor cells evade death signals and acquire multi-drug resistance (MDR) is the deregulation of apoptosis, frequently through the overexpression of anti-apoptotic proteins of the B-cell lymphoma-2 (Bcl-2) family [1]. To counteract this, pharmacological modulation of apoptosis has emerged as a promising therapeutic strategy. ABT-737 was developed as a highly potent, synthetic small-molecule inhibitor with BH3-mimetic effects [3]. By competitively binding to anti-apoptotic Bcl-2 proteins, ABT-737 prevents the sequestration of pro-apoptotic proteins, thereby lowering the apoptotic threshold and resensitizing resistant tumor cells to cytotoxic agents and targeted therapies [1][5].
2. Pharmacological Activity
ABT-737 has demonstrated significant pharmacological activity across a wide spectrum of solid and hematological malignancies, particularly in the context of reversing drug resistance. As a single agent, it has shown high efficacy in small cell lung cancer (SCLC) and various hematological cell lines, including leukemias, multiple myeloma, and lymphomas [1][3]. In non-small cell lung carcinoma (NSCLC), ABT-737 effectively reverses resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) and enhances erlotinib-mediated cell death [2][4].
In pediatric hepatoblastoma (HB), ABT-737 potentiates the efficacy of established chemotherapeutic drugs such as cisplatin, paclitaxel, doxorubicin, and etoposide, significantly reducing tumor cell proliferation and tumor growth in xenograft models [1]. Furthermore, ABT-737 induces apoptosis in HTLV-1-associated adult T-cell leukemia/lymphoma (ATLL) by restoring the balance between pro- and anti-apoptotic signaling [6], and synergizes with chemotherapy to kill head and neck squamous cell carcinoma (HNSCC) cells [7]. Interestingly, beyond oncology, ABT-737 has exhibited neuroprotective properties by inactivating ΔN-Bcl-xL, thereby protecting hippocampal neurons from ischemia-induced cell death [9].
3. Molecular Mechanism of Action
The primary mechanism of action of ABT-737 involves the activation of the intrinsic mitochondrial apoptotic pathway. ABT-737 acts as a BH3-mimetic, attaching with high affinity to the hydrophobic groove of anti-apoptotic proteins Bcl-2, Bcl-xL, and Bcl-w [2][3]. This binding displaces sequestered pro-apoptotic BH3-containing proteins, such as BIM, BAX, and BAK [3]. Once liberated, BAX and BAK oligomerize and induce mitochondrial outer membrane permeabilization, leading to the release of cytochrome c, activation of caspase-3, cleavage of PARP, and ultimately, cell death [2][3][4].
In the context of drug resistance reversal, ABT-737 modulates several critical signaling pathways. In EGFR-mutant NSCLC, ABT-737 restores BIM functionality, overcoming resistance to EGFR-TKIs [2]. It also lowers the apoptotic threshold by inhibiting PI3K/Akt signaling, which otherwise promotes cancer cell survival [2][4]. Additionally, ABT-737 upregulates Noxa expression and activates the JNK (c-Jun) signaling pathway, which further enhances BIM expression and reinstates sensitivity to agents like paclitaxel and ionizing radiation [2][4].
4. Structure-Activity Relationship (SAR)
The discovery and optimization of ABT-737 represent a landmark in fragment-based drug design. It was developed using Structure-Activity Relationship by Nuclear Magnetic Resonance (SAR by NMR) to screen chemical libraries for fragments that bind to the hydrophobic groove of Bcl-xL [3][8]. Researchers identified two small chemical compounds that bound to distinct pockets (P2 and P4) within the Bcl-xL BH3 domain. By linking and modifying these proximal fragments, ABT-737 was synthesized [8].
Structurally, ABT-737 binds with sub-nanomolar affinity (Ki < 1 nM) to Bcl-xL, Bcl-2, and Bcl-w due to the high structural homology of their active sites [3][8]. However, it exhibits very low affinity for other anti-apoptotic proteins, specifically MCL-1, BCL-B, and BCL2A1 (A1). This lack of binding is attributed to a less homologous structure in the hydrophobic binding pockets of these specific proteins, rendering them resistant to ABT-737 inhibition [1][3].
5. Current Limitations
Despite its potent preclinical efficacy, the clinical translation of ABT-737 has been hindered by several significant limitations. First, ABT-737 is not orally bioavailable, which restricts its dosing regimens, particularly for chronic therapy [3]. Second, it possesses unfavorable pharmacological features, most notably dose-limiting thrombocytopenia. This toxicity is an on-target side effect resulting from the inhibition of Bcl-xL, a protein that is absolutely critical for the survival and lifespan of mature platelets [2][3][5].
Furthermore, tumor cells frequently develop resistance to ABT-737 through the overexpression of MCL-1. Because ABT-737 cannot inhibit MCL-1, high levels of this protein can take over the function of the inhibited Bcl-2/Bcl-xL proteins, sequestering the displaced pro-apoptotic factors (like BIM or BAX) and preventing apoptosis [1][3]. This MCL-1 dependency represents a major escape mechanism for cancer cells treated with ABT-737.
6. Future Perspectives
To overcome the limitations of ABT-737, next-generation BH3-mimetics have been developed. ABT-263 (Navitoclax) was synthesized to provide oral bioavailability while maintaining a similar target profile, though it still causes thrombocytopenia [3][5]. Subsequently, ABT-199 (Venetoclax) was engineered as a highly selective Bcl-2 inhibitor that spares Bcl-xL, thereby achieving potent antitumor activity without inducing severe platelet toxicity [3][5].
Future therapeutic strategies heavily emphasize rational combination therapies. Combining ABT-737 (or its derivatives) with agents that downregulate or inhibit MCL-1—such as specific MCL-1 inhibitors, anthracyclines, or inhibitors of the PI3K/mTOR pathway—can synergistically induce apoptosis and overcome resistance [2][3]. Additionally, combining BH3-mimetics with targeted kinase inhibitors (e.g., MEK, BRAF, or EGFR inhibitors) has shown great promise. For instance, MEK/ERK inhibition induces the expression of pro-apoptotic BH3-only proteins, which primes the tumor cells for apoptosis, converting a cytostatic response into a cytotoxic one when combined with ABT-737 [3]. These stratified, biomarker-driven combination approaches hold the key to maximizing the clinical utility of Bcl-2 family inhibitors in reversing drug resistance across diverse malignancies.
